These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 37376813)
1. Efruxifermin, an investigational treatment for fibrotic or cirrhotic nonalcoholic steatohepatitis (NASH). Puengel T; Tacke F Expert Opin Investig Drugs; 2023; 32(6):451-461. PubMed ID: 37376813 [TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis. Harrison SA; Ruane PJ; Freilich B; Neff G; Patil R; Behling C; Hu C; Shringarpure R; de Temple B; Fong E; Tillman EJ; Rolph T; Cheng A; Yale K JHEP Rep; 2023 Jan; 5(1):100563. PubMed ID: 36644237 [TBL] [Abstract][Full Text] [Related]
3. Pegbelfermin (BMS-986036): an investigational PEGylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis. Verzijl CRC; Van De Peppel IP; Struik D; Jonker JW Expert Opin Investig Drugs; 2020 Feb; 29(2):125-133. PubMed ID: 31899984 [No Abstract] [Full Text] [Related]
4. Noncompetitive immunoassay optimized for pharmacokinetic assessments of biologically active efruxifermin. Kinne AS; Tillman EJ; Abdeen SJ; Johnson DE; Parmer ES; Hurst JP; de Temple B; Rinker S; Rolph TP; Bowsher RR J Pharm Biomed Anal; 2023 Aug; 232():115402. PubMed ID: 37141854 [TBL] [Abstract][Full Text] [Related]
5. FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases. Tillman EJ; Rolph T Front Endocrinol (Lausanne); 2020; 11():601290. PubMed ID: 33381084 [TBL] [Abstract][Full Text] [Related]
6. The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. Abdelmalek MF; Charles ED; Sanyal AJ; Harrison SA; Neuschwander-Tetri BA; Goodman Z; Ehman RA; Karsdal M; Nakajima A; Du S; Tirucherai GS; Klinger GH; Mora J; Yamaguchi M; Shevell DE; Loomba R Contemp Clin Trials; 2021 May; 104():106335. PubMed ID: 33657443 [TBL] [Abstract][Full Text] [Related]
7. Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis. Puengel T; Lefere S; Hundertmark J; Kohlhepp M; Penners C; Van de Velde F; Lapauw B; Hoorens A; Devisscher L; Geerts A; Boehm S; Zhao Q; Krupinski J; Charles ED; Zinker B; Tacke F Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743140 [TBL] [Abstract][Full Text] [Related]
8. Anti-diabetic drugs and NASH: from current options to promising perspectives. Smati S; Canivet CM; Boursier J; Cariou B Expert Opin Investig Drugs; 2021 Aug; 30(8):813-825. PubMed ID: 34214406 [No Abstract] [Full Text] [Related]
9. Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes. Barb D; Bril F; Kalavalapalli S; Cusi K J Clin Endocrinol Metab; 2019 Aug; 104(8):3327-3336. PubMed ID: 30848827 [TBL] [Abstract][Full Text] [Related]
10. Hepatoprotective effects of the long-acting fibroblast growth factor 21 analog PF-05231023 in the GAN diet-induced obese and biopsy-confirmed mouse model of nonalcoholic steatohepatitis. Nielsen MH; Gillum MP; Vrang N; Jelsing J; Hansen HH; Feigh M; Oró D Am J Physiol Gastrointest Liver Physiol; 2023 May; 324(5):G378-G388. PubMed ID: 36852934 [TBL] [Abstract][Full Text] [Related]
11. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH. Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280 [TBL] [Abstract][Full Text] [Related]
12. Promising therapies for treatment of nonalcoholic steatohepatitis. Noureddin M; Zhang A; Loomba R Expert Opin Emerg Drugs; 2016 Sep; 21(3):343-57. PubMed ID: 27501374 [TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics and management of patients with nonalcoholic steatohepatitis in a real-world setting: analysis of the Ipsos NASH therapy monitor database. Shelley K; Articolo A; Luthra R; Charlton M BMC Gastroenterol; 2023 May; 23(1):160. PubMed ID: 37208593 [TBL] [Abstract][Full Text] [Related]
14. Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease. Brown E; Hydes T; Hamid A; Cuthbertson DJ Clin Ther; 2021 Sep; 43(9):1476-1504. PubMed ID: 34446271 [TBL] [Abstract][Full Text] [Related]
15. Approach to the Patient With Nonalcoholic Fatty Liver Disease. Belfort-DeAguiar R; Lomonaco R; Cusi K J Clin Endocrinol Metab; 2023 Jan; 108(2):483-495. PubMed ID: 36305273 [TBL] [Abstract][Full Text] [Related]
16. Targeting FGF21 for the Treatment of Nonalcoholic Steatohepatitis. Zarei M; Pizarro-Delgado J; Barroso E; Palomer X; Vázquez-Carrera M Trends Pharmacol Sci; 2020 Mar; 41(3):199-208. PubMed ID: 31980251 [TBL] [Abstract][Full Text] [Related]